Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis

Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis

Objective: To identify predictors of clinical disease activity after treatment change to higher-dose interferon beta-1a in relapsing-remitting multiple sclerosis (MS).Methods: This was a retrospective-prospective observational multicenter study. We enrolled patients with at least one relapse on plat...

Full description

Bibliographic Details
Main Authors: Martina Novotna, Ales Tvaroh, Jan Mares
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
relapse
progression
disease activity
interferon beta
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00944/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2020.00944/full

Similar Items